Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

Will oversee launch of new medicines and Otsuka partnership respectively

Danish pharma firm Lundbeck has promoted Andreas Eggert to senior VP for global product strategy and Klaus Abel to VP with responsibility for commercialisation of medicines from Lundbeck's partnership with Otsuka Pharmaceuticals.

Eggert, who joined Lundbeck in 2010 as VP for global product strategy, will have overall responsibility for the launches of several new medicines from Lundbeck during the next 18 months, including vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.

Prior to joining Lundbeck, Eggert spent several years at Wyeth (now part of Pfizer) where his roles included serving as director global strategic marketing and VP and global business manager.

Andreas Eggert - LundbeckKlaus Abel - Lundbeck
Andreas Eggert and Klaus Abel

Abel's responsibilities will cover the collaborative development and commercialisation of medicines Lundbeck is working on with Otsuka as part of a multi-billion dollar deal, including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.

Abel, who has been with Lundbeck since 2000, and was most recently executive director with commercial responsibility for several products, will report to Eggert who will in turn report directly to president and CEO Ulf Wiinberg.

23rd August 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics